RecruitingNCT06496360

Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer

Prediction Model of Mediastinal Group IV Lymph Node Metastasis in Non-small Cell Lung Cancer Based on CT Radiomics


Sponsor

Qilu Hospital of Shandong University

Enrollment

150 participants

Start Date

Aug 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Mediastinal lymph node metastasis is a common metastasis pathway of non-small cell lung cancer (NSCLC), and its occurrence is closely related to the lymphatic drainage pattern, which is different in different pulmonary lobe NSCLC, which poses a challenge for the formulation of individualized treatment strategies. Accurate staging is the prerequisite for accurate treatment of NSCLC. Computed Tomograph (CT) examination is an important tool for evaluating mediastinal lymph node metastasis, which is crucial for making treatment plan and evaluating patient prognosis. However, it is difficult to diagnose metastatic lymph nodes with insignificant imaging features. Especially metastatic lymph nodes in areas 4 and 7. Both zone 4 and zone 7 are hot spots for mediastinal lymph node metastasis. However, clinical guidelines do not make clear provisions on lymph node dissection in zone 4, which makes preoperative clinical staging and prognosis evaluation of patients with NSCLC particularly important. By integrating and analyzing a large amount of data in CT images, the newly emerging CT radiomics technology captures subtle features that may be overlooked in conventional CT scans, showing great application prospects in the accuracy of non-invasive diagnosis of lymph node metastasis. This study aims to explore the mediastinal drainage pattern and the role of CT in evaluating mediastinal lymph node metastasis, in order to provide valuable imaging evidence for accurately judging mediastinal lymph node metastasis of NSCLC, formulating appropriate lymph node dissection scope, optimizing treatment strategy, and improving patient prognosis.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is looking at ways to predict whether lung cancer has spread to lymph nodes in the chest (called mediastinal station 4 nodes), using CT scan images taken before surgery. **You may be eligible if...** - You have been diagnosed with non-small cell lung cancer (NSCLC) and had surgery to remove it, including lymph node removal - You had a chest CT scan with contrast dye within 2 weeks before surgery - Your CT scan images are clear and complete medical records are available - Lymph nodes at station 4 were tested during surgery **You may NOT be eligible if...** - You received chemotherapy or radiation before surgery - You have cancer that has spread to other parts of the body, or have another cancer - Your medical records or scan images are incomplete or of poor quality - No station 4 lymph nodes were examined during surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTArtificial Intelligence

The model employs machine learning algorithms to analyze CT imaging data of patients with non-small cell lung cancer. It focuses on the identification and assessment of features of the mediastinal fourth group lymph nodes, including size, shape, margins, and density. By extracting features related to lymph node metastasis, the model assists doctors in making more accurate diagnoses.


Locations(1)

Qilu Hospital of Shandong University

Jinan, Shandong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06496360


Related Trials